These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 15076165)

  • 1. Eprosartan improves cardiac performance, reduces cardiac hypertrophy and mortality and downregulates myocardial monocyte chemoattractant protein-1 and inflammation in hypertensive heart disease.
    Behr TM; Willette RN; Coatney RW; Berova M; Angermann CE; Anderson K; Sackner-Bernstein JD; Barone FC
    J Hypertens; 2004 Mar; 22(3):583-92. PubMed ID: 15076165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eprosartan reduces cardiac hypertrophy, protects heart and kidney, and prevents early mortality in severely hypertensive stroke-prone rats.
    Barone FC; Coatney RW; Chandra S; Sarkar SK; Nelson AH; Contino LC; Brooks DP; Campbell WG; Ohlstein EH; Willette RN
    Cardiovasc Res; 2001 Jun; 50(3):525-37. PubMed ID: 11376628
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hemodynamic and cardiac effects of chronic eprosartan and moxonidine therapy in stroke-prone spontaneously hypertensive rats.
    Mukaddam-Daher S; Menaouar A; Paquette PA; Jankowski M; Gutkowska J; Gillis MA; Shi YF; Calderone A; Tardif JC
    Hypertension; 2009 May; 53(5):775-81. PubMed ID: 19273740
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monocyte chemoattractant protein-1 and macrophage infiltration in hypertensive kidney injury.
    Hilgers KF; Hartner A; Porst M; Mai M; Wittmann M; Hugo C; Ganten D; Geiger H; Veelken R; Mann JF
    Kidney Int; 2000 Dec; 58(6):2408-19. PubMed ID: 11115074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enrasentan improves survival, limits left ventricular remodeling, and preserves myocardial performance in hypertensive cardiac hypertrophy and dysfunction.
    Willette RN; Anderson KM; Nelson AH; Olzinski AR; Woods T; Coatney RW; Aiyar N; Ohlstein EH; Barone FC
    J Cardiovasc Pharmacol; 2001 Oct; 38(4):606-17. PubMed ID: 11588531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The angiotensin type 1 receptor antagonist, eprosartan, attenuates the progression of renal disease in spontaneously hypertensive stroke-prone rats with accelerated hypertension.
    Abrahamsen CT; Barone FC; Campbell WG; Nelson AH; Contino LC; Pullen MA; Grygielko ET; Edwards RM; Laping NJ; Brooks DP
    J Pharmacol Exp Ther; 2002 Apr; 301(1):21-8. PubMed ID: 11907153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Upregulation of ligand, receptor system, and amidating activity of adrenomedullin in left ventricular hypertrophy of severely hypertensive rats: effects of angiotensin-converting enzyme inhibitors and diuretic.
    Wang X; Nishikimi T; Akimoto K; Tadokoro K; Mori Y; Minamino N
    J Hypertens; 2003 Jun; 21(6):1171-81. PubMed ID: 12777955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of long-term eprosartan versus enalapril antihypertensive therapy on left ventricular mass and coronary flow reserve in stage I-II hypertension. Eprosartan Study Group.
    Diamond JA; Gharavi A; Roychoudhury D; Machac J; Henzlova MJ; Travis A; Phillips RA
    Curr Med Res Opin; 1999; 15(1):1-8. PubMed ID: 10216805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiotensin II receptor antagonist TCV-116 induces regression of hypertensive left ventricular hypertrophy in vivo and inhibits the intracellular signaling pathway of stretch-mediated cardiomyocyte hypertrophy in vitro.
    Kojima M; Shiojima I; Yamazaki T; Komuro I; Zou Z; Wang Y; Mizuno T; Ueki K; Tobe K; Kadowaki T
    Circulation; 1994 May; 89(5):2204-11. PubMed ID: 8181146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic effects of angiotensin II type 1 receptor blocker at an advanced stage of hypertensive diastolic heart failure.
    Nishio M; Sakata Y; Mano T; Yoshida J; Ohtani T; Takeda Y; Miwa T; Masuyama T; Yamamoto K; Hori M
    J Hypertens; 2007 Feb; 25(2):455-61. PubMed ID: 17211254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficacy and tolerance of one or two daily doses of eprosartan in essential hypertension. The Eprosartan Multinational Study Group.
    Hedner T; Himmelmann A
    J Hypertens; 1999 Jan; 17(1):129-36. PubMed ID: 10100104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Losartan reduces monocyte chemoattractant protein-1 expression in aortic tissues of 2K1C hypertensive rats.
    Xie QY; Sun M; Yang TL; Sun ZL
    Int J Cardiol; 2006 Jun; 110(1):60-6. PubMed ID: 16242797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exaggerated blood pressure variability superimposed on hypertension aggravates cardiac remodeling in rats via angiotensin II system-mediated chronic inflammation.
    Kudo H; Kai H; Kajimoto H; Koga M; Takayama N; Mori T; Ikeda A; Yasuoka S; Anegawa T; Mifune H; Kato S; Hirooka Y; Imaizumi T
    Hypertension; 2009 Oct; 54(4):832-8. PubMed ID: 19704105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atorvastatin prevents connexin43 remodeling in hypertrophied left ventricular myocardium of spontaneously hypertensive rats.
    Chen HJ; Yao L; Chen TG; Yu M; Wang LH; Chen JZ
    Chin Med J (Engl); 2007 Nov; 120(21):1902-7. PubMed ID: 18067764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and failure in low-aldosterone hypertensive rats.
    Nagata K; Obata K; Xu J; Ichihara S; Noda A; Kimata H; Kato T; Izawa H; Murohara T; Yokota M
    Hypertension; 2006 Apr; 47(4):656-64. PubMed ID: 16505208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carvedilol prevents and reverses hypertrophy-induced cardiac dysfunction.
    Barone FC; Willette RN; Nelson AH; Ohlstein EH; Brooks DP; Coatney RW
    Pharmacology; 2007; 80(2-3):166-76. PubMed ID: 17551266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-monocyte chemoattractant protein-1 gene therapy attenuates left ventricular remodeling and failure after experimental myocardial infarction.
    Hayashidani S; Tsutsui H; Shiomi T; Ikeuchi M; Matsusaka H; Suematsu N; Wen J; Egashira K; Takeshita A
    Circulation; 2003 Oct; 108(17):2134-40. PubMed ID: 14517168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of eprosartan on renal function and cardiac hypertrophy in rats with experimental heart failure.
    Brodsky S; Gurbanov K; Abassi Z; Hoffman A; Ruffolo RR; Feuerstein GZ; Winaver J
    Hypertension; 1998 Oct; 32(4):746-52. PubMed ID: 9774374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of late-onset and long-term captopril and nifedipine treatment in aged spontaneously hypertensive rats: Echocardiographic studies.
    Zimmer J; Hawlitschek C; Rabald S; Hagendorff A; Zimmer HG; Rassler B
    Hypertens Res; 2015 Nov; 38(11):716-22. PubMed ID: 26178152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of eprosartan on cytoplasmic free calcium mobilization, platelet activation, and microparticle formation in hypertension.
    Labiós M; Martínez M; Gabriel F; Guiral V; Munoz A; Aznar J
    Am J Hypertens; 2004 Sep; 17(9):757-63. PubMed ID: 15363816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.